A Phase 1 interventional study of DWRX5003 and DWC202502 in Obesity & Overweight and Type 2 Diabetes, sponsored by Daewoong Pharmaceutical Co. LTD.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 137 studies in Obesity with a site in Korea, Republic of — 35 open to participants now, 46 under way, 27 of them phase 3. Obesity · Korea, Republic of.
Among the 137 studies in Obesity with a site in Korea, Republic of, this one is the 81st largest by planned enrollment of the 117 interventional ones that give a count, is one of 22 that started in 2026, is one of 9 in phase 1, reaches primary completion later than 13 of the 45 other live ones, and was the 120th registered.
11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
Browse Obesity studies →35 of the 137 studies in Obesity with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Korea, Republic of, United States, Argentina and 8 more countries
Ages 18+
Eli Lilly and Company · Sites in Korea, Republic of, United States, Belgium and 7 more countries
Ages 6–11
AstraZeneca · Sites in Korea, Republic of, United States, Argentina and 13 more countries
Ages 18+
AstraZeneca · Sites in Korea, Republic of, United States, Argentina and 13 more countries
Ages 18+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19–50
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 19 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 49 · Phase 4 7
First in 2005; this study’s year is marked. 22 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is close to the median of 67 across 9,036 interventional studies indexed under Obesity.
Median enrollment 120 across the 117 interventional studies, 704 across the 20 observational. Of the 76 that completed or were terminated, 10 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 137 have an industry lead sponsor. The 10 most frequent:
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Daewoong Pharmaceutical Co. LTD. has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
10 of the studies in Obesity with a site in Korea, Republic of that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 10 to your calendar (.ics) → With an account.
Among the 137 studies in Obesity with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 1 Safety and Relative Bioavailability Study of DWRX5003 in Healthy Adults
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DWRX5003 3 doses
Drug: DWRX5003
Drug: DWC202502
Drug: DWC202503
Other: DWRX5003P
Microneedle patch containing Semaglutide
Semagluide
Semaglutide
placebo microneedle patch
This study also gives Semaglutide. No intervention listed here names it: that was found by reading the record.
AUC 0-t
Time frame: Pre-dose (0 hour) up to 672 hours post-dose
Cmax
Time frame: Pre-dose (0 hour) up to 672 hours post-dose
AUC 0-8h, AUC 0-168h, AUCinf
Time frame: Pre-dose (0 hour) up to 672 hours post-dose
CL/F, Vd/F
Clearance, Volume of distribution
Time frame: Pre-dose (0 hour) up to 672 hours post-dose
Tmax, t½
Tmax (time to reach maximum plasma concentration), t½ (elimination half-life)
Time frame: Pre-dose (0 hour) up to 672 hours post-dose
Frel
Relative bioavailability compared to the active control
Time frame: Pre-dose (0 hour) up to 672 hours post-dose
AUEC0-5h, AUEC5-10h, iAUC0-5h, iAUC5-10h
Time frame: Baseline (Day -1) to Day 8
Emax of glucose
Time frame: Baseline (Day -1) to Day 8
AUEC0-168h, AUEC0-672h of glucose
Time frame: Baseline (Day -1) to Day 8
body weight
Time frame: baseline (day -1 ) to day 29
BMI
Time frame: baseline (day -1 ) to day 29
waist circumference
Time frame: baseline (day -1 ) to day 29
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Oct 2026, 5 months after the start.
Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 5 months is below that.
Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide
Daewoong Pharmaceutical Co. LTD. →